T
his is the second of three reports on the 35th Annual Meeting of the European Association for the Study of Diabetes (EASD) held in Brussels in September 1999. It covers topics related to the ␤-cell, the role of antibodies in type 1 diabetes, pancreas and islet transplantation, obesity, and insulin resistance.
The ␤-Cell Cosgrove et al. (abstract 231) studied intact islets and single cells isolated from a diettreated patient with type 2 diabetes who suffered a fatal myocardial infarction (MI). Only 3 of 11 islet cells possessed functional ATP-sensitive K ϩ (K ATP ) channels, compared with all recordings from 164 control human ␤-cells. In those cells that possessed K ATP channels, there were no effects of intracellular nucleotides or tolbutamide on channel activity. Only 5 of 10 cells possessed functional voltage-dependent Ca 2ϩ channels, compared with all recordings from 67 control cells (n = 67), and the currents in the ␤-cells in the patient with diabetes were approximately half those in control cells. Thus, type 2 diabetes may be associated with loss of ion channel function and disruption of cytosolic Ca 2ϩ signaling events.
Rustenbeck et al. (abstract 480) studied the effect of prolonged stimulation of pancreatic islets by inhibitors of K ATP channels in decreasing in vitro islet insulin secretory responsiveness, showing that K ATP channels remain responsive but that the ability to increase intracellular calcium levels decreases. Similarly, McClenaghan et al.
(abstract 479) reported that prolonged exposure to tolbutamide downregulates both K ATP -channel-dependent and -independent insulin-secretory actions of this agent. In a related study, Barnes et al. (abstract 482) showed that the thiazide diuretic hydrochlorothiazide, which can impair glucose tolerance, is an agonist of K ATP channels in ␤-cells. It inhibits glucose-and tolbutamide-stimulated insulin release, while activating K ATP channels and reversing ATP-induced channel inhibition, again showing that prolonged channel activation acts distal to the channel to impair insulin secretion.
In another report addressing calcium signaling in the islets, Squires et al. (abstract 494) used reverse transcription-polymerase chain reaction to show expression of the parathyroid calcium receptor on ␣-and ␤-cells. Incubation with calcium induced a transient increase in intracellular calcium 59% of that seen with tolbutamide, suggesting that the calcium receptor affects insulin secretion independent of sustained change in intracellular calcium levels. Finally, addressing another potential regulatory mechanism, Josefsen et al. (abstract 245) reported that naloxone increased glucose-induced insulin release by rat islets in vitro approximately 2-fold after stimulation at 4.5 and 11 mmol/l glucose, suggesting a tonic inhibitory effect of endogenous opioid peptides. Incubation with dynorphin 1-17, dynorphin 1-13, or Met-or Leu-enkephalin did not have a suppressive effect.
Wily Gepts Memorial Lecture
Daniel Pipeleers, Brussels, Belgium, discussed ␤-cells in diabetes in a memorial lecture honoring Wily Gepts, who established the pathology of the pancreas in type 1 diabetes more than 3 decades ago. One finding of Pipeleers' s work is the presence of new islets developing adjacent to duct cells in patients with onset of diabetes in early childhood. Duct cells are required for expression of islet NO synthase. NO acts as an inflammatory mediator. Duct cells may also be involved in cytokine-mediated HLA expression, suggesting that they may act as antigen-presenting cells.
Pipeleers hypothesizes that some of the heterogeneity of islet loss among different lobes of the pancreas in a given patient may be related to differences in duct cell factors. In patients with older age of onset, there is more evidence of fibrosis, suggesting either that there were inflammatory lesions earlier or that additional processes are involved in islet loss. These patients often have hyperplastic islets, suggesting that "the ␤-cells should not be considered as passive victims." Instead, they play a role in antigen presentation and modulate the immune system response, and they may also have adaptations aimed at preserving islet function.
Another area of Pipeleers' s work has been to assess the mediators of islet cytotoxicity and whether the mechanism of cell death is necrosis or apoptosis. In an in vitro model, oxidant factors cause necrosis and low glucose causes both necrosis and apoptosis, while levels over ϳ10 mmol/l are protective. This paradoxical finding suggests that the inability to respond to glucose underlies ␤-cell loss, primarily in Pipeleers' s work involving apoptosis. Interleukin-1, interferon-␥, and tumor necrosis factor-␣ decrease levels of the islet glucose transporter GLUT2, while increasing superoxide dismutase and NO synthase, and there is evidence that the ␤-cell phenotype can be transformed to one less able to respond to Zachary T. Bloomgarden, MD, is a practicing endocrinologist in New York, New York, and is affiliated with the Division of Endocrinology, Mount Sinai School of Medicine, New York, New York.
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Bloomgarden glucose and more prone to apoptosis, perhaps an important process in the development of type 1 diabetes.
Discussing the ␤-cell in type 2 diabetes, Pipeleers pointed out that chronic stimulation in the insulin-resistant setting, perhaps mediated by high glucose and free fatty acid levels, is associated with decreasing ␤-cell function. This may also be associated with a change in ␤-cell phenotype to one showing decreased glucose uptake and increased susceptibility to apoptosis. As in type 1 diabetes, there is heterogeneity of distribution of abnormal ␤-cells in the pancreas of the patient with type 2 diabetes, which can be shown by the distribution of amyloid deposits. Amyloid may require a high fat intake for expression, with a relevant pathological finding being the presence of lipidstorage lysozymal vesicles in ␤-cells in humans, increasing with age and taking up circulating LDL and VLDL particles.
Two studies presented at the meeting addressed additional abnormalities of the pancreas in type 2 diabetes. Rathmann et al. (abstract 297) found fecal elastase-1 Ͻ100 µg/g stool, which suggests pancreatic exocrine insufficiency, in 11.8% of 526 patients with type 2 diabetes and 3.8% of 526 nondiabetic age-and sex-matched control subjects. The presence was associated with a higher HbA 1c level, but not with diabetes duration or peripheral neuropathy. In an examination of 122 patients at the time of diagnosis of type 2 diabetes, Katsaros et al. (abstract 298) found levels of the tumor marker CA-19-9 Ͼ900 U/ml in 5 patients, who were found to have pancreatic cancer, suggesting a potential screening modality. An additional 5 patients had levels between 80 and 100, with negative computed tomography scans.
Autoimmunity in Type 1 Diabetes
Decochez et al. (abstract 222) followed 172 type 1 diabetic patients Ͻ40 years of age for 2 years. C-peptide values decreased to Ͻ0.15 µg/l in 88% of patients diagnosed before age 7 years, in 45% diagnosed between ages 7 and 15 years, and in 29% diagnosed after age 15 years. In the latter group, 25 of 70 patients (36%) with islet cell antibody (ICA) titers Ͼ12 JDF U developed low C-peptide levels, compared with 5 of 35 (14%) with lower ICA levels. With diabetes onset before age 15 years, a rapid decline in C-peptide was observed in 34 of 49 patients with ICA Ͼ50 JDF U at diagnosis versus 3 of 18 with lower ICA titers. Glutamate decarboxylase (GADA) and IA-2 protein antibodies did not predict the fall in C-peptide level. The authors suggested that ␤-cellpreserving strategies should primarily be tested in the high-ICA subgroup and that this assay measures clinically relevant antibodies that are not detected in the molecular antibody assays using recombinant human islet cell autoantigens as substrate.
Petersen (abstract 820) reported that 6 of 9 patients with type 1 diabetes and blood glucose Ͻ40 mg/dl at least once weekly had pathologic results in at least 1 neuropsychological test of memory; there were no pathologic results in 9 age-and education-matched control subjects without diabetes.
Perspectives on the News
Islet and Pancreas Transplantation Ritzel et al. (abstract 117) compared 7 patients with type 1 diabetes and pancreastransplantation using portal-venous drainage and 8 patients with the usual systemic-venous drainage of the pancreas graft vein anastomosis to the iliac veins. Basal and stimulated insulin levels were significantly lower after portal-venous drainage, suggesting this procedure to be advantageous. Lohmann et al. (abstract 359) reported that treatment with the immunosuppressive drug tacrolimus, which may lead to development of diabetes, was associated with islet-cell antibodies in 5 of 22 liver-transplant patients, but that cyclosporin A did not produce antibodies in 20 similar patients after liver transplantation. Three of the 5 antibody-positive patients and 2 antibody-negative patients developed diabetes. Use of this drug may not, therefore, be appropriate in patients with type 1 diabetes after pancreas transplantation.
P. Marchetti, Pisa, Italy, discussed animal studies pertaining to islet transplantation. The pancreatic islets comprise 1-2% of the pancreatic mass, with 300,000-1,000,000 islets per pancreas. Islet transplantation is simple, with feasibility of storage and possible in vitro modification of islet immunogenicity. Since the first studies, this research has attracted great attention, but it remains beset by problems (2) . Preparation factors involve the chemicals used; the presence of small amounts of endotoxin, which may be particularly damaging to islets; and the storage procedures, with cryopreservation potentially decreasing islet mass and function.
Immunosuppressive treatment offers another potentially toxic factor that may impair islet engraftment. The number of islets transplanted is crucial, with 6,000/kg body wt appearing to be the minimum. The purity of the transplanted islets is a potential problem, but interestingly, islets completely separated from pancreatic parenchyma appear to show increased apoptosis, suggesting the need for trophic factors not produced in the islets themselves. The optimal location for the transplant remains uncertain; the liver is best physiologically, but some studies suggest that subcapsular renal transplants show increased survival. Another potential difficulty is the establishment of islet innervation and revascularization.
Immune factors, not only involving specific immune rejection but with macrophage-mediated "nonspecific" immunity and recurrence of the autoimmune islitis (3), are major issues. It is fascinating that autoimmunity is less of a problem with whole-pancreas than with islet-cell transplantation. The findings that islet autografts in diabetic patients undergoing pancreatectomy have ϳ7-fold longer survival than allografts and that allografts for patients without type 1 diabetes have ϳ5-fold longer survival suggests the importance of these factors.
Metabolic factors impairing the function of the transplanted islets include glucotoxicity and lipotoxicity, with elevated glucose and fat levels potentially increasing cytokine levels around the transplanted islets. Potential solutions include new immunosuppressants, including antibodies to CD154 lymphocytes (4); encapsulation of transplanted islets, although this may paradoxically cause local hypoxia and decreased graft function; and eventually, genetic manipulation of xenograft islets.
Antonio Secchi, Milan, Italy, concluded with a review of the current state of clinical human islet transplantation, pointing out the basic problem that so few individuals make arrangements to make organ donations. Only several hundred islet transplants have been performed, somewhat more in Europe than in the U.S. Giessen, Germany (5), and Milan, Italy (6), where 60 and 30 islet transplants have been performed, are the largest centers.
Insulin Resistance
Plasma cell membrane glycoprotein-1 (PC-1) inhibits insulin receptor tyrosine kinase activity and subsequent cellular signaling. Frittitta et al. (abstract 72) reported an association of the PC-1 gene polymorphism K121Q with insulin resistance in 121 healthy subjects and 135 type 2 diabetic patients. Bavenholm et al. (abstract 98) measured hepatic glucose production and glucose requirement during insulin infusion in 29, 10, and 15 men with normal, impaired, or diabetic glucose tolerance. They found that 41% of the variability in glycemic response to glucose was explained by the degree of decrease in hepatic glucose production in response to insulin, 18% by extra-hepatic insulin sensitivity, and 12% by the insulin response, with hepatic sensitivity to insulin being the most important factor both in those with and in those without diabetes.
NO deficiency may play a role in insulin resistance. A number of genetic abnormalities associated with obesity were reported at the EASD meeting. Shnawa et al. (abstract 286) found that 26% of 70 women with gestational diabetes but 11% of women with normal glucose tolerance had the Trp 64 Arg missense mutation polymorphism of the ␤ 3 -adrenergic receptor, potentially predisposing to obesity. Branchtein et al. (abstract 978) reported that height Յ151 cm was associated with a 60% increase in risk of gestational diabetes independent of age, obesity, family history of diabetes, ethnicity, education, or gestational age.
de Silva et al. (abstract 71) studied 311 males from Nauru with BMI 36 and 483 Australian women with BMI 27 for polymorphism in the tumor necrosis factor (TNF)-␣ gene. The Nco1 polymorphism at position Ϫ308 of the TNF-␣ promoter region that has been associated with increased gene transcription was not seen in the Nauruans, but was seen in 21% of the Australian group. Individuals who were homozygotic for this polymorphism had lower fasting insulin, suggesting increased insulin sensitivity. Wauters et al. (abstract 73) reported on 32 women aged 45-60 years with IGT or diabetes in whom significant associations were found between the Lys 109 Arg polymorphism of the leptin receptor and fasting insulin and 2-h insulin response during an oral glucose tolerance test. In a report that may have bearing on the risks associated with obesity, Niskanen et al. (abstract 1206) reported that a Leu 7 Pro polymorphism in the prepro-neuropeptide Y gene, present in 10 and 14% of individuals with and without diabetes, was associated with increased carotid intimamedia thickness, independent of age, sex, diabetes, clinical macrovascular disease, smoking, systolic blood pressure, or LDL cholesterol.
Segal et al. (abstract 171) randomized 359 normal, IGT, and diabetic patients to treatment with orlistat (120 mg t.i.d.) and 316 normal, IGT, and diabetic patients to placebo plus hypocaloric diet. Weight loss was 6.9 and 7.2% with orlistat in normal and IGT subjects; 5% in diabetic patients; and 4, 3.4, and 3.8% in the 3 groups given placebo. LDL decreased 9.8, 8.2, and 3.3% in the 3 groups given orlistat; it decreased 1.2 and 2.2% in normal and IGT patients given placebo and increased 7.3% in the diabetic patients given placebo. Changes in triglyceride, HDL, and blood pressure were inconsistent and minimal in all groups.
Wilding (abstract 807) pooled data from 5 multicenter, 2-year, randomized, placebo-controlled trials of orlistat in 1,561 patients and placebo in 1,119 patients with BMI 28-43. Weight loss after 1 year was 9.2 and 5.8%, and after an additional year on a weight maintenance diet, weight loss was 6.7 and 3.7%. The homeostasis model insulin resistance index, calculated as insulin (pmol/l) ϫ glucose (mmol/l) ÷ 22.5, decreased 0.51 from placebo at 1 year and 0.84 from placebo at 2 years.
Rigalleau et al. (abstract 731) addressed the effect of insulin on body weight and body fat measured using body-impedance analysis 3 months after initiation of insulin treatment. In 24 patients with type 1 diabetes, there was a 2.5-kg weight gain without change in body fat, while in 12 patients with type 2 diabetes, there was a 1-kg weight gain with a 0.6-kg increase in body fat. Twelve patients with type 2 diabetes discontinuing insulin showed a 1.3-kg weight loss with a 0.9-kg fall in fat mass after 3 months.
